Form 4: Ionis Pharma EVP Exercises Options, Sells Shares

Ionis Pharmaceuticals EVP of Research, Eric Swayze, exercised stock options, sold common stock, and received new option grants on January 2, 2026, under a Rule 10b5-1 plan.

Summary

• Eric Swayze, EVP Research at Ionis Pharmaceuticals Inc. (IONS), engaged in multiple equity transactions on January 2, 2026.
• Exercised non-qualified stock options to acquire 5,125 shares of common stock at an exercise price of $60.89 per share.
• Exercised additional non-qualified stock options to acquire 18,338 shares of common stock at an exercise price of $60.89 per share.
• Sold 5,125 shares of common stock at a weighted average price of $78.57 per share, with prices ranging from $78.155 to $78.88.
• Sold 18,338 shares of common stock at a weighted average price of $79.27 per share, with prices ranging from $78.88 to $79.70.
• All sales were conducted pursuant to a Rule 10b5-1 Trading Plan adopted on August 14, 2024.
• Received a grant of 19,350 non-qualified stock options with an exercise price of $79.67 per share, vesting over four years starting January 2, 2027.
• An additional 150 non-qualified stock options were granted to the reporting person's son, with an exercise price of $79.67 per share and the same vesting schedule.
• Following these transactions, direct beneficial ownership of common stock is 30,453 shares, and indirect ownership by son is 256 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While there is insider selling, it's under a pre-planned 10b5-1 arrangement, which mitigates negative sentiment. The executive also received new option grants, indicating continued long-term incentive and alignment with company performance.

Positives

• The exercise of stock options indicates that the executive realized value from previously granted equity incentives.
• The grant of new stock options to the EVP Research and his son demonstrates continued alignment of executive incentives with shareholder interests and a long-term commitment to the company's performance.

Negatives

• The sale of common stock by a key executive, even under a pre-arranged plan, represents a reduction in their direct equity stake in the company.

Future Outlook

Newly granted non-qualified stock options will begin vesting on January 2, 2027, with 25% vesting on that date, and the remaining shares vesting in 36 equal monthly installments over the subsequent three years. These options have an expiration date of January 1, 2036.

Industry Context

This Form 4 filing details routine insider equity transactions for an executive at a biotechnology company. Such transactions are common in the industry as part of executive compensation and personal financial planning, often executed under pre-arranged trading plans.

Corporate Governance

Related Party Transactions

• A grant of 150 non-qualified stock options was made to the reporting person's son under the company's equity incentive plan.

Stakeholder Impact

• Shareholders gain transparency into executive compensation and equity management practices through the disclosure of option exercises, stock sales, and new grants.
• Employees (specifically the EVP Research) are impacted by changes in their equity holdings and long-term incentive structures.

Next Steps

• The newly granted stock options will begin their vesting schedule on January 2, 2027, with subsequent monthly vesting installments over the following three years.

Key Dates

Keywords

IONIS PHARMACEUTICALS, IONS, Form 4, insider trading, stock options, equity compensation, executive compensation, Rule 10b5-1, beneficial ownership